Novo Nordisk A/S (NVO)

DK — Healthcare Sector
Peers: REGN  CRSP  SRPT  NTLA  MRNA  CVAC  NVAX  CWBR  RETA  BNTX  DNA  VRTX  BMRN  SGEN  ALNY  MDGL  ICPT  TGTX  TERN  HEPA 

Automate Your Wheel Strategy on NVO

With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NVO
  • Rev/Share 68.2827
  • Book/Share 31.2062
  • PB 14.5232
  • Debt/Equity 0.857
  • CurrentRatio 0.7386
  • ROIC 0.3875

 

  • MktCap 2011672953933.6895
  • FreeCF/Share 16.8361
  • PFCF 26.9142
  • PE 19.2328
  • Debt/Assets 0.2427
  • DivYield 0.0227
  • ROE 0.8124

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade NVO BMO Capital Markets Outperform Market Perform -- $64 April 17, 2025
Upgrade NVO Kepler Hold Buy -- -- March 13, 2025
Downgrade NVO Stifel Buy Hold -- -- March 3, 2025
Initiation NVO Morgan Stanley -- Equal Weight -- -- Feb. 12, 2025
Upgrade NVO Bernstein Underperform Market Perform -- -- Jan. 6, 2025

News

Novo Nordisk: The Market Doesn't Get It
NVO
Published: July 11, 2025 by: Seeking Alpha
Sentiment: Positive

Novo Nordisk remains dominant in diabetes and obesity care, with strong growth and expanding market share despite recent investor concerns. The company's pipeline, especially the oral GLP-1 and Alzheimer's trial, offers significant long-term upside. The company needs to grow its top-line at mid-% to justify its current valuation. By assuming the market growth rate, the company is massively undervalued.

Read More
image for news Novo Nordisk: The Market Doesn't Get It
Smart Money Going in Senior Health: Key Stocks in Elderly Care
EW, NVO, RHHBY, SYK
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Neutral

RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.

Read More
image for news Smart Money Going in Senior Health: Key Stocks in Elderly Care
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
NVO
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.

Read More
image for news Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
HIMS, NVO
Published: July 09, 2025 by: CNBC
Sentiment: Positive

Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.

Read More
image for news Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
BMY, GILD, JNJ, NVO, PFE, RHHBY, VRTX
Published: July 08, 2025 by: CNBC
Sentiment: Negative

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

Read More
image for news Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
NVO
Published: July 08, 2025 by: Reuters
Sentiment: Positive

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.

Read More
image for news Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
HIMS, NVO
Published: July 07, 2025 by: Benzinga
Sentiment: Negative

Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company's stock has plummeted approximately 18% over the past month, reflecting recent challenges.

Read More
image for news Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
NVO
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
Are You Looking for a High-Growth Dividend Stock?
NVO
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?

Read More
image for news Are You Looking for a High-Growth Dividend Stock?
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
NVO
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

Read More
image for news Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
GSK, NVO
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
NVO
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive

Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding threats are overblown; FDA enforcement and strategic partnerships will redirect demand to branded Wegovy. An oral semaglutide approval later this year can help reignite share price momentum.

Read More
image for news Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
NVO
Published: July 01, 2025 by: CNBC Television
Sentiment: Positive

Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.

Read More
image for news Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
NVO
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read More
image for news Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
6 International Stocks To buy in July
ASML, BTI, NVO, SHOP, TSM, VALE
Published: June 27, 2025 by: 24/7 Wall Street
Sentiment: Positive

With over $5 trillion of new investment commitments to date, the U.S.

Read More
image for news 6 International Stocks To buy in July
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
LLY, NVO
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.

Read More
image for news NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
NVO, WGHTQ
Published: June 26, 2025 by: WSJ
Sentiment: Positive

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

Read More
image for news Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
Novo Nordisk ties up with WeightWatchers to sell Wegovy
NVO, WGHTQ
Published: June 26, 2025 by: Reuters
Sentiment: Positive

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1.

Read More
image for news Novo Nordisk ties up with WeightWatchers to sell Wegovy
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
NVO
Published: June 26, 2025 by: PRNewsWire
Sentiment: Neutral

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing A new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® PLAINSBORO, N.J. , June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy® (semaglutide) injection 2.4 mg through a new collaboration with …

Read More
image for news Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
NVO
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

Read More
image for news CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
NVO
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

Read More
image for news Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
Hims & Hers: The Novo Nordisk Breakup Changes Nothing
HIMS, NVO
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a GLP-1 play. HIMS' core value lies in its broad treatment offerings and disruptive model, not in partnerships with big pharma like NVO. Legal risks remain, but I believe HIMS is well-positioned to defend itself, and no legal action has been initiated by NVO yet.

Read More
image for news Hims & Hers: The Novo Nordisk Breakup Changes Nothing
EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
NVO
Published: June 23, 2025 by: Reuters
Sentiment: Positive

Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.

Read More
image for news EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
NVO
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

Read More
image for news Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Novo Nordisk Ends Partnership with Hims & Hers
HIMS, NVO
Published: June 23, 2025 by: WSJ
Sentiment: Negative

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.

Read More
image for news Novo Nordisk Ends Partnership with Hims & Hers
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
NVO
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive

Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.

Read More
image for news NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
HIMS, NVO
Published: June 23, 2025 by: Proactive Investors
Sentiment: Negative

Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding and marketing of the weight-loss drug Wegovy. Novo said it ended Hims & Hers' access to the FDA-approved treatment through its NovoCare platform, alleging that the company engaged in illegal mass compounding and deceptive marketing.

Read More
image for news Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
Novo Nordisk under pressure, ends deal with Hims & Hers
HIMS, NVO
Published: June 23, 2025 by: CNBC Television
Sentiment: Negative

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.

Read More
image for news Novo Nordisk under pressure, ends deal with Hims & Hers
Novo Nordisk, Hims and Hers Shares Tumble on Severed Ties
HIMS, NVO
Published: June 23, 2025 by: Schaeffers Research
Sentiment: Negative

Novo Nordisk A/S (NYSE:NVO) stock is down 5.3% to trade at $69.90 at last check, after the drugmaker's obesity drug CagriSema showed no clear advantage over Eli Lilly's (LLY) Zepbound.

Read More
image for news Novo Nordisk, Hims and Hers Shares Tumble on Severed Ties
Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
HIMS, NVO
Published: June 23, 2025 by: Barrons
Sentiment: Negative

Novo Nordisk accuses the telehealth company of breaking a law related to drug compounding.

Read More
image for news Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership

About Novo Nordisk A/S (NVO)

  • IPO Date 1981-04-30
  • Website https://www.novonordisk.com
  • Industry Drug Manufacturers - General
  • CEO Lars Fruergaard Jorgensen
  • Employees 77406

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.